Management of sarcopenia in patients with rheumatoid arthritis
Modern Rheumatology · 13.04.2023 · 33 (3) · 435-440
DOI: 10.1093/mr/roac095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Modern Rheumatology, online erschienen am 20.08.2022. Verfasst von Mie Torii und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Sarcopenia, Arthritis, Rheumatoid. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science KAKENHI, Research Funding for Longevity Sciences.
Abstract (Originalsprache)
This review summarizes the evidence for the management of sarcopenia in patients with rheumatoid arthritis (RA) in terms of drugs, exercise, and nutrition. Sarcopenia is a decrease in skeletal muscle mass and muscle strength or physical function. The prevalence of sarcopenia in patients with RA is higher than that in the general population. The treatment and management of sarcopenia in patients with RA are clinically important for long-term prognosis. One of the mechanisms of muscle metabolism is the pro-inflammatory cytokine pathway, which involves tumour necrosis factor α and interleukin-6, and is a common pathway in the pathogenesis of RA. Thus, tumour necrosis factor α and interleukin-6 inhibitors may play a potential role in controlling sarcopenia. In exercise therapy, a combination of moderate resistance and aerobic exercise may be effective in improving muscle strength, muscle mass, and physical function; however, intense exercise may exacerbate the inflammatory response in RA. Regarding nutrition, protein intake is generally considered beneficial, but other nutrients such as vitamin D and carotenoids have also been studied. Overall, there remains a lack of concrete evidence on sarcopenia treatment and management in patients with RA from any perspective; more longitudinal and intervention studies are needed in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
- Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan.
- Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science KAKENHI
- Research Funding for Longevity Sciences
- National Center for Geriatrics and Gerontology
Zitieren
APA
Torii, M., Itaya, T., Minamino, H., Katsushima, M., Fujita, Y., Tanaka, H., Oshima, Y., Watanabe, R., Ito, H., Arai, H., & Hashimoto, M. (2023). Management of sarcopenia in patients with rheumatoid arthritis. Modern Rheumatology, 33(3), 435-440. https://doi.org/10.1093/mr/roac095
Vancouver
Torii M, Itaya T, Minamino H, Katsushima M, Fujita Y, Tanaka H, et al. Management of sarcopenia in patients with rheumatoid arthritis. Modern Rheumatology. 2023;33(3):435-440. doi:10.1093/mr/roac095
BibTeX
@article{Torii2023,
author = {Torii, Mie and Itaya, Takahiro and Minamino, Hiroto and Katsushima, Masao and Fujita, Yoshihito and Tanaka, Hiroki and Oshima, Yohei and Watanabe, Ryu and Ito, Hiromu and Arai, Hidenori and Hashimoto, Motomu},
title = {Management of sarcopenia in patients with rheumatoid arthritis},
journal = {Modern Rheumatology},
year = {2023},
volume = {33},
number = {3},
pages = {435--440},
doi = {10.1093/mr/roac095}
}
EUVIMED